Overview

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Status:
Completed

Trial end date:
2017-09-15

Target enrollment:

Participant gender:

Summary

This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel
Trastuzumab